专注于肿瘤学的人工智能分子诊断平台Caris Life Sciences（股票代码：CAI）今日在纳斯达克上市，盘中大涨28.57%，引发市场关注。
Caris Life Sciences此次IPO定价为每股21美元，高于此前上调后的19至20美元区间，共发行2350万股股票，募资4.94亿美元。按IPO价格计算，Caris Life Sciences的完全稀释后市值达61亿美元，较最初预期高出17%。
Caris Life Sciences是一家基于人工智能的精准医疗公司，通过下一代测序、人工智能和机器学习技术，开发用于治疗癌症的精准医学诊断解决方案。公司表示，其平台基于超过650万次测试的数据集，在超过84.9万例病例中运行，并产生了超过380亿个分子标记的测量结果。投资者对Caris Life Sciences在癌症诊断领域的创新技术和未来增长潜力表现出强烈兴趣，推动了股价的大幅上涨。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.